{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:25:32Z","timestamp":1790058332813,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T00:00:00Z","timestamp":1516665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute\/NIH","doi-asserted-by":"crossref","award":["R01CA213131"],"award-info":[{"award-number":["R01CA213131"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute\/NIH","doi-asserted-by":"crossref","award":["P50CA107399"],"award-info":[{"award-number":["P50CA107399"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute\/NIH","doi-asserted-by":"crossref","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"STOP-CANCER Foundation"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ymthe.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T21:35:21Z","timestamp":1516138521000},"page":"695-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors"],"prefix":"10.1016","volume":"26","author":[{"given":"Xingli","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayson","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haejung","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Adamus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei H.","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Swiderski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju K.","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kortylewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.01.007_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2018.01.007_bib2","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2311::AID-CNCR13>3.0.CO;2-X","article-title":"The National Cancer Data Base report on non-Hodgkin\u2019s lymphoma","volume":"80","author":"Glass","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2018.01.007_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2018.01.007_bib4","doi-asserted-by":"crossref","first-page":"a001719","DOI":"10.1101\/mcs.a001719","article-title":"Diffuse large B-cell lymphoma: can genomics improve treatment options\u00a0for a curable cancer?","volume":"3","author":"Amin","year":"2017","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.ymthe.2018.01.007_bib5","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2009.019745","article-title":"Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma","volume":"95","author":"Baran-Marszak","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2018.01.007_bib6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.01.007_bib7","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2013.52.8414","article-title":"Transcription factor STAT3 as a prognostic marker and therapeutic target in cancer","volume":"31","author":"Frank","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib8","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2012.45.6004","article-title":"Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP","volume":"31","author":"Huang","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib9","first-page":"5113","article-title":"Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma","volume":"20","author":"Ok","year":"2014","journal-title":"Clin\u00a0Cancer Res."},{"key":"10.1016\/j.ymthe.2018.01.007_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.01.007_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 signaling in immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2018.01.007_bib12","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-\u03baB pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.01.007_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib14","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1074\/jbc.M405204200","article-title":"Interleukin-12-induced interferon-gamma production by human peripheral blood T\u00a0cells is regulated by mammalian target of rapamycin (mTOR)","volume":"280","author":"Kusaba","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2018.01.007_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib16","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.4049\/jimmunol.1400833","article-title":"Noncanonical NF-\u03baB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer","volume":"193","author":"Yu","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib17","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2018.01.007_bib18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1073\/pnas.0237137100","article-title":"STAT3 deletion during hematopoiesis causes Crohn\u2019s disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity","volume":"100","author":"Welte","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.01.007_bib19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2012-07-442590","article-title":"TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in\u00a0vivo","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.01.007_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4161\/jkst.22312","article-title":"Nucleic acid-based approaches to STAT inhibition","volume":"1","author":"Sen","year":"2012","journal-title":"JAK-STAT"},{"key":"10.1016\/j.ymthe.2018.01.007_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejphar.2014.05.047","article-title":"Comparative screening and validation as a novel tool to identify STAT-specific inhibitors","volume":"740","author":"Szel\u0105g","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib22","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2018.01.007_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4155\/tde.13.152","article-title":"Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?","volume":"5","author":"Kortylewski","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ymthe.2018.01.007_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/nat.2012.0340","article-title":"CpG still rocks! Update on an accidental drug","volume":"22","author":"Krieg","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2018.01.007_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1564","article-title":"In\u00a0vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses","volume":"27","author":"Kortylewski","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jconrel.2013.06.007","article-title":"Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape","volume":"170","author":"Nechaev","year":"2013","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2018.01.007_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2013-07-517987","article-title":"Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity","volume":"123","author":"Hossain","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.01.007_bib29","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-14-3145","article-title":"TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients","volume":"21","author":"Hossain","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.01.007_bib30","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","article-title":"B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides","volume":"11","author":"Jahrsdorfer","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.01.007_bib31","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/10428190903115410","article-title":"The role of toll-like receptors in chronic B-cell malignancies","volume":"50","author":"Muzio","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ymthe.2018.01.007_bib32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20131424","article-title":"Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance","volume":"211","author":"Wang","year":"2014","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2018.01.007_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/gene.2011.59","article-title":"The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma","volume":"13","author":"Carvalho","year":"2012","journal-title":"Genes Immun."},{"key":"10.1016\/j.ymthe.2018.01.007_bib34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2015-08-665604","article-title":"Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.01.007_bib35","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-07-0815","article-title":"Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin\u2019s lymphoma","volume":"13","author":"Leonard","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.01.007_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.cji.0000211304.60126.8f","article-title":"Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma","volume":"29","author":"Link","year":"2006","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2018.01.007_bib37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/ni.2391","article-title":"Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways","volume":"13","author":"Murray","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/0008-5472.CAN-08-3031","article-title":"Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy","volume":"69","author":"Kortylewski","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.01.007_bib39","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1158\/0008-5472.CAN-13-1314","article-title":"TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy","volume":"73","author":"Gao","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2018.01.007_bib40","first-page":"316","article-title":"Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin\u2019s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis","volume":"9","author":"Alas","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2018.01.007_bib41","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1534\/g3.113.007674","article-title":"STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma","volume":"3","author":"Hardee","year":"2013","journal-title":"G3 (Bethesda)"},{"key":"10.1016\/j.ymthe.2018.01.007_bib42","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","article-title":"Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent","volume":"128","author":"Xiang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.01.007_bib43","doi-asserted-by":"crossref","first-page":"6772","DOI":"10.1182\/blood-2010-12-319780","article-title":"Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412","volume":"118","author":"R\u00f6mer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2018.01.007_bib44","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.179.4.2493","article-title":"Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself","volume":"179","author":"Li","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib45","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.4049\/jimmunol.1001869","article-title":"Presentation of soluble antigens to CD8+ T\u00a0cells by CpG oligodeoxynucleotide-primed human naive B cells","volume":"186","author":"Jiang","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.01.007_bib46","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/CJI.0b013e3181ab23f1","article-title":"Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma","volume":"32","author":"Betting","year":"2009","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2018.01.007_bib47","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/CJI.0b013e318261e679","article-title":"Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma","volume":"35","author":"Betting","year":"2012","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2018.01.007_bib48","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","article-title":"Depleting tumor-specific Tregs at a single site eradicates disseminated tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2018.01.007_bib49","doi-asserted-by":"crossref","first-page":"e27441","DOI":"10.4161\/onci.27441","article-title":"Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity","volume":"3","author":"Kortylewski","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ymthe.2018.01.007_bib50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1074-7613(03)00232-2","article-title":"A critical role for Stat3 signaling in immune tolerance","volume":"19","author":"Cheng","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2018.01.007_bib51","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4161\/cbt.29453","article-title":"Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model","volume":"15","author":"Cao","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2018.01.007_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2018.01.007_bib53","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2310\/7290.2009.00007","article-title":"In\u00a0vivo pharmacodynamic imaging of proteasome inhibition","volume":"8","author":"Kimbrel","year":"2009","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.ymthe.2018.01.007_bib54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1535-7163.261.3.3","article-title":"Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity","volume":"3","author":"Turkson","year":"2004","journal-title":"Mol. Cancer Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618300145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001618300145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:52:55Z","timestamp":1761501175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618300145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1525001618300145"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.007","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.02.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors.","name":"copyright","label":"Copyright"}]}}